Experience with SARS-CoV-2 (COVID-19) Assay Validation

April 14, 2020

Experience with SARS-CoV-2 (COVID-19) Assay Validation

Case Study

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In this 20-minute eCase Study you will hear first-hand how Dr. Jeff SoRelle and team, of the University of Texas Southwestern Medical Center, developed and validated a COVID-19 RT PCR assay. Dr. SoRelle shares his decision to bring this development in house, how he chose reference materials, and how he managed to scale up and provide rapid turnaround.

Breaking News

The Scan

Herbert Tabor Dies

The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.

Funds to Get Vaccines

The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.

A Number on It

Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.

Nucleic Acids Research Studies on 3D SARS-CoV-2 Structures, Human Brain Atlas, More

In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.

Featured White Papers

Development of Matched Maternal-Fetal Noninvasive Prenatal Testing (NIPT) Reference Materials Compatible with a Broad Range of Assay Methods

Development and performance of a formalin-damaged multiplexed DNA tumor mutation FFPE reference material

Development of Reference Material for Blood Tumor Mutational Burden Measurement

Reference Materials for Measurable Residual Disease (MRD) Monitoring

Oct

27

Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

Menu